Itacitinib - Incyte Corporation

Drug Profile

Itacitinib - Incyte Corporation

Alternative Names: INCB-039110; INCB-039110-adipate; INCB-39110; Itacitinib-adipate

Latest Information Update: 28 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Incyte Corporation
  • Developer AstraZeneca; Incyte Corporation
  • Class Antineoplastics; Antipsoriatics; Antirheumatics; Small molecules
  • Mechanism of Action Janus kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Graft-versus-host disease
  • Phase II Hodgkin's disease; Myelofibrosis; Non-small cell lung cancer
  • Phase I/II Non-Hodgkin's lymphoma; Solid tumours
  • Discontinued Pancreatic cancer; Plaque psoriasis; Rheumatoid arthritis

Most Recent Events

  • 21 Jun 2018 Massachusetts General Hospital, Incyte Pharmaceuticals and Sundry plan a phase I trial for Malignant melanoma and Solid tumours (Combination therapy) in USA (NCT03272464)
  • 21 Jun 2018 University of Pennsylvania plans a phase II trial for Non small cell lung cancer (Combination therapy, First-line therapy; Metastatic disease) in June 2018 , (NCT03425006)
  • 20 Mar 2018 Phase-I clinical trials in Graft-versus-host disease (Combination therapy) in Japan (PO) (NCT03497273)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top